STLN

The Oncology Institute, Inc.

$4.34

8.50%
SectorHealthcareIndustryMedical Care FacilitiesCountryUnited States

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc.

Source: Yahoo Finance
AI summary

Price & performance

1M-1.5%
3M+22.2%
YTD+75.2%
1Y+69.7%
52-week range—
Beta1.27
Full chart and returns against a benchmark

Q-Score

57/ 100

Quality against peers; 50 is the peer median.

Growth72
Risk41
Performance70
Valuation61
Profitability45
Leverage45
Sentiment52
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$502.7M+27.8%
Net income-$60.6M
Net margin-12.1%+4.4 pts
Historical fundamentals

Red flags in filings

1active red flag
Cybersecurity incidentMay 22, 2026
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer14%
Regions, segments, customers and suppliers

Valuation

STLNIndustryP/E—12.66P/S0.711.15EV/EBITDA—13.41P/B—7.42PEG—0.49
Dividend yield0.00%
Every valuation metric

Earnings

Nov 5next report
EPS estimate—
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate